INOZYME PHARMA, INC. Retained Earnings
INOZYME PHARMA, INC. had Retained Earnings of -$415.99 million as of 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2025-05-14
- 2025-03-31: Retained Earnings (Accumulated Deficit) -$415.99M.
- 2024-12-31: Retained Earnings (Accumulated Deficit) -$387.95M.
- 2024-09-30: Retained Earnings (Accumulated Deficit) -$360.88M.
- 2024-06-30: Retained Earnings (Accumulated Deficit) -$336.31M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2025-03-31 | -$415.99M 10-Q · filed 2025-05-14 |
| 2024-12-31 | -$387.95M 10-Q · filed 2025-05-14 |
| 2024-09-30 | -$360.88M 10-Q · filed 2024-11-05 |
| 2024-06-30 | -$336.31M 10-Q · filed 2024-08-06 |
| 2024-03-31 | -$309.28M 10-Q · filed 2024-05-07 |
| 2023-12-31 | -$285.93M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$264.39M 10-Q · filed 2023-11-07 |
| 2023-06-30 | -$247.75M 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$232.16M 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$214.76M 10-K · filed 2024-03-12 |
| 2022-09-30 | -$196.22M 10-Q · filed 2022-11-10 |
| 2022-06-30 | -$179.84M 10-Q · filed 2022-08-15 |
| 2022-03-31 | -$164.58M 10-Q · filed 2022-05-10 |
| 2021-12-31 | -$147.70M 10-K · filed 2023-03-22 |
| 2021-09-30 | -$128.95M 10-Q · filed 2021-11-09 |
| 2021-06-30 | -$114.67M 10-Q · filed 2021-08-11 |
| 2021-03-31 | -$102.13M 10-Q · filed 2021-05-12 |
| 2020-12-31 | -$91.08M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$79.96M 10-Q · filed 2020-11-12 |
| 2020-06-30 | -$51.86M 10-Q · filed 2020-09-03 |
| 2019-12-31 | -$34.65M 10-K · filed 2021-03-25 |